<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116813</url>
  </required_header>
  <id_info>
    <org_study_id>ADX48621-302</org_study_id>
    <nct_id>NCT05116813</nct_id>
  </id_info>
  <brief_title>Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy</brief_title>
  <official_title>An Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addex Pharma S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addex Pharma S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study is designed to assess the long-term safety and tolerability of&#xD;
      dipraglurant in PD patients for up to 52 weeks (1 week at 150 mg per day and 11 weeks at 300&#xD;
      mg per day) for patients that have completed an Addex sponsored double-blind clinical trial&#xD;
      of dipraglurant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety and tolerability of dipraglurant as measured by incidence of adverse events</measure>
    <time_frame>Baseline (Day 1) to Week 52</time_frame>
    <description>Testing the safety and tolerability of dipraglurant in patients with Parkinson's Disease Levodopa-induced dyskinesia based on the incidence of adverse events reported by patients and/or as identified by the Investigator based on clinical assessments conducted during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the continued utility of dipraglurant on dyskinesia as assessed by a change-from-baseline score on the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS).</measure>
    <time_frame>Baseline (Day 1) to Week 52</time_frame>
    <description>The MDS-UPDRS is a Parkinson's Disease (PD) rating scale scored from 0-272; it evaluates progression of disease in patients with PD. A higher score indicates more severe PD.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Dyskinesia, Drug-Induced</condition>
  <condition>Dyskinesias</condition>
  <arm_group>
    <arm_group_label>Dipraglurant TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipraglurant</intervention_name>
    <description>Oral 50mg and 100mg tablet</description>
    <arm_group_label>Dipraglurant TID</arm_group_label>
    <other_name>ADX48621</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completed an Addex randomized controlled study of dipraglurant and, in the judgement&#xD;
             of the Investigator, may benefit from open-label treatment&#xD;
&#xD;
          -  Able to take study drug 3 times daily and no less than 3 hours apart&#xD;
&#xD;
          -  Must be taking levodopa not less than 3 times daily throughout the study&#xD;
&#xD;
          -  Must maintain stable regimen of antiparkinson's medications (including levodopa) and&#xD;
             be willing to continue the same doses and regimens for the first 4 weeks of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is judged by the Investigator to be inappropriate for the study (for reasons&#xD;
             such as, but not limited to, significant noncompliance in the Addex randomized&#xD;
             controlled study of dipraglurant)&#xD;
&#xD;
          -  Use of amantadine or amantadine ER throughout the study&#xD;
&#xD;
          -  Use of memantine throughout the study&#xD;
&#xD;
          -  Any use of marijuana or other cannabis/cannabinoid products for the first 4 weeks of&#xD;
             study participation&#xD;
&#xD;
        Other protocol-defined inclusion and exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>877-409-1775</phone>
    <email>Clinical.Team@addexpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariane Park</last_name>
      <phone>614-293-4969</phone>
      <email>park.485@osu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Dyskinesia</keyword>
  <keyword>Levodopa-induced Dyskinesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Dyskinesia, Drug-Induced</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

